A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T‑Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 26 Mar 2018
At a glance
- Drugs BNZ 1 (Primary)
- Indications Cutaneous T-cell lymphoma; Lymphoid leukaemia
- Focus Adverse reactions
- Sponsors Bioniz
- 31 Aug 2018 Biomarkers information updated
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.
- 17 Jan 2018 Planned End Date changed from 30 Apr 2018 to 30 Dec 2018.